WO2008109558A3 - Nucleic acid compounds for inhibiting tlr gene expression and uses thereof - Google Patents

Nucleic acid compounds for inhibiting tlr gene expression and uses thereof Download PDF

Info

Publication number
WO2008109558A3
WO2008109558A3 PCT/US2008/055711 US2008055711W WO2008109558A3 WO 2008109558 A3 WO2008109558 A3 WO 2008109558A3 US 2008055711 W US2008055711 W US 2008055711W WO 2008109558 A3 WO2008109558 A3 WO 2008109558A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
gene expression
tlr
acid compounds
mdrna
Prior art date
Application number
PCT/US2008/055711
Other languages
French (fr)
Other versions
WO2008109558A2 (en
WO2008109558A4 (en
Inventor
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Original Assignee
Mdrna Inc
Steven C Quay
James Mcswiggen
Narendra K Vaish
Mohammad Ahmadian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mdrna Inc, Steven C Quay, James Mcswiggen, Narendra K Vaish, Mohammad Ahmadian filed Critical Mdrna Inc
Publication of WO2008109558A2 publication Critical patent/WO2008109558A2/en
Publication of WO2008109558A3 publication Critical patent/WO2008109558A3/en
Publication of WO2008109558A4 publication Critical patent/WO2008109558A4/en
Priority to US12/552,082 priority Critical patent/US20100105134A1/en
Priority to US13/327,545 priority patent/US20130011922A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides meroduplex ribonucleic acid molecules (mdRNA) capable of decreasing or silencing TLR (e.g., TLR3, TLR7, TLR8, or TLR9) gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to a TLR3, TLR7, TLR8, or TLR9 mRNA. In addition, the meroduplex may have at least one uridine is a 5-methyluridine, a nucleoside is a locked nucleic acid, or optionally other modifications, and any combination thereof. Also provided are methods of decreasing expression of a TLR gene in a cell or in a subject to treat a TLR-related disease.
PCT/US2008/055711 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting tlr gene expression and uses thereof WO2008109558A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/552,082 US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US13/327,545 US20130011922A1 (en) 2007-03-02 2011-12-15 Nucleic acid compounds for inhibiting gene expression and uses thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US93494007P 2007-03-02 2007-03-02
US60/934,940 2007-03-02
US93493007P 2007-03-16 2007-03-16
US60/934,930 2007-03-16
US98840507P 2007-11-15 2007-11-15
US60/988,405 2007-11-15
US98942807P 2007-11-20 2007-11-20
US98942407P 2007-11-20 2007-11-20
US98942707P 2007-11-20 2007-11-20
US60/989,427 2007-11-20
US60/989,428 2007-11-20
US60/989,424 2007-11-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055635 Continuation-In-Part WO2008109511A1 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting fcer2 gene expression and uses thereof

Related Child Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2008/055649 Continuation-In-Part WO2008109518A1 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
AU2009212920A Division AU2009212920A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof
US12/552,082 Continuation-In-Part US20100105134A1 (en) 2007-03-02 2009-09-01 Nucleic acid compounds for inhibiting gene expression and uses thereof

Publications (3)

Publication Number Publication Date
WO2008109558A2 WO2008109558A2 (en) 2008-09-12
WO2008109558A3 true WO2008109558A3 (en) 2009-02-05
WO2008109558A4 WO2008109558A4 (en) 2009-04-02

Family

ID=39739059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/055711 WO2008109558A2 (en) 2007-03-02 2008-03-03 Nucleic acid compounds for inhibiting tlr gene expression and uses thereof

Country Status (1)

Country Link
WO (1) WO2008109558A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049078A1 (en) 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
US8772243B2 (en) * 2008-08-20 2014-07-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8
CA2752694A1 (en) * 2009-02-10 2010-08-19 Idera Pharmaceuticals, Inc. Synthetic rna-based agonists of tlr7
EP3753922A4 (en) * 2018-09-07 2021-08-18 Korea Advanced Institute Of Science And Technology Composition for detecting dsrnas, comprising merocyanine compound and isomer thereof, and method for providing information for diagnosing cancer, by using dsrna expression analysis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
WO2007056153A2 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
WO2008049078A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085443A2 (en) * 2004-03-01 2005-09-15 Massachusetts Institute Of Technology Rnai-based therapeutics for allergic rhinitis and asthma
WO2007056153A2 (en) * 2005-11-04 2007-05-18 Nastech Pharmaceutical Company Inc. Peptide-dicer substrate rna conjugates as delivery vehicles for sirna
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
WO2008049078A1 (en) * 2006-10-18 2008-04-24 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ALVES M.P. ET AL.: "Toll-like Receptor 7 and MyD88 knockdown by lentivirus-mediated RNA interference to porcine dendritic cell subsets", GENE THERAPY, vol. 14, 1 March 2007 (2007-03-01), pages 836 - 844, XP002505444 *
BIN QIAO ET AL.: "Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation", CELLULAR & MOLECULAR IMMUNOLOGY, vol. 2, no. 2, April 2005 (2005-04-01), pages 130 - 135, XP002505447 *
BRAMSEN JESPER B. ET AL.: "Improved silencing properties using small internally segmented interfering RNAs", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 35, no. 17, 28 July 2007 (2007-07-28), pages 5886 - 5897, XP002458184, ISSN: 0305-1048 *
FLANDIN J.-F. ET AL.: "RNA interference reveals a role for TLR2 and TLR3 in the recognition of Leishmania donovani promastigotes by interferon-gamma-primed macrophages", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 36, 2006, pages 411 - 420, XP002505442 *
HAGERMAN K.R. AND HAGERMAN P.J.: "Helix rigidity of DNA: the meroduplex as an experimental paradigm", JOURNAL OF MOLECULAR BIOLOGY, vol. 260, 1996, pages 207 - 223, XP002484999 *
HORNUNG V. ET AL.: "Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7", NATURE MEDICINE, vol. 11, no. 3, March 2005 (2005-03-01), pages 263 - 270, XP002505448 *
HUANG X. ET AL.: "Silencing Toll-like Receptor 9 in Pseudomonas aeruginosa keratitis", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 46, no. 11, November 2005 (2005-11-01), pages 4209 - 4216, XP002505450 *
LEUSCHNER P J F ET AL: "Cleavage of the siRNA passenger strand during RISC assembly in human cells", EMBO REPORTS, XX, XX, vol. 7, no. 3, 1 March 2006 (2006-03-01), pages 314 - 320, XP002467845 *
LI K. ET AL.: "Distinct poly(I-C) and virus-activated signaling pathways leading to Interferon-beta production in hepatocytes", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 17, 29 April 2005 (2005-04-29), pages 16739 - 16747, XP002505439 *
LIU P. ET AL.: "Retinoic acid-Inducible Gene I mediates early antiviral response and Toll-like Receptor 3 expression in Respiratory Syncitial Virus-infected airway epithelial cells", JOURNAL OF VIROLOGY, vol. 81, no. 3, February 2007 (2007-02-01), pages 1401 - 1411, XP002505440 *
MILLS JANINE B. ET AL.: "Origin of the intrinsic rigidity of DNA", NUCLEIC ACIDS RESEARCH,, vol. 32, no. 13, 1 January 2004 (2004-01-01), pages 4055 - 4059, XP002484664 *
NAKA K. ET AL.: "Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 346, no. 2, 15 March 2006 (2006-03-15), pages 348 - 362, XP005326321, ISSN: 0042-6822 *
NIIMI K. ET AL.: "TLR3-mediated synthesis and release of Eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA", THE JOURNAL OF IMMUNOLOGY, vol. 178, 1 January 2007 (2007-01-01), pages 489 - 495, XP002505441 *
PARILLA N.W. ET AL.: "CpG DNA modulates interleukin 1[beta]-induced interleukin-8 expression in human bronchial epithelial (16HBE14o-) cells", RESPIRATORY RESEARCH, BIOMED CENTRAL LTD., LONDON, GB, vol. 7, no. 1, 1 June 2006 (2006-06-01), pages 84, XP021013363, ISSN: 1465-9921 *
RUDD B.D. ET AL.: "Differential role for TLR3 in Respiratory Syncitial Virus-induced chemokine expression", JOURNAL OF VIROLOGY, vol. 79, no. 6, March 2005 (2005-03-01), pages 3350 - 3357, XP002505438 *
SAJJAN U.S. ET AL.: "H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression", THE FASEB JOURNAL, vol. 20, 2006, pages E1419 - E1429, XP002505437 *
TRIANTAFILOU K. ET AL.: "Human cardiac inflammatory responses triggered by Coxsachie B viruses are mainly Toll-like receptor (LTR) 8-dependent", CELLULAR MICROBIOLOGY, vol. 7, no. 8, 2005, pages 1117 - 1126, XP002505446 *
TRIANTAFILOU K. ET AL.: "TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 35, 2005, pages 2416 - 2423, XP002505445 *
WANG R. ET AL.: "HSP70 enhances macrophage phagocytosis by interaction with lipid raft-associated TLR-7 and upregulating p38 MAPK and PI3K pathways", JOURNAL OF SURGICAL RESEARCH, ACADEMIC PRESS INC., SAN DIEGO, CA, US, vol. 136, no. 1, 1 November 2006 (2006-11-01), pages 58 - 69, XP005717143, ISSN: 0022-4804 *
YANG X. ET AL.: "Toll-like Receptor 3 signaling evokes a proinflammatory and proliferative phenotype in human vascular smooth muscle cells", AMERICAN JOURNAL OF PHYSIOLOGY - HEART AND CIRCULATORY PHYSIOLOGY, vol. 291, 2006, pages H2334 - H2343, XP002505443 *

Also Published As

Publication number Publication date
WO2008109558A2 (en) 2008-09-12
WO2008109558A4 (en) 2009-04-02

Similar Documents

Publication Publication Date Title
WO2008109472A3 (en) Nucleic acid compounds for inhibiting pcsk9 gene exprression and uses thereof
WO2008109381A3 (en) Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
WO2008116860A3 (en) Dsrna compositions and methods for treating hpv infections
WO2008109516A3 (en) Nucleic acid compounds for inhibiting ras gene expression and uses thereof
WO2010017319A3 (en) Nucleic acid compounds for inhibiting plk1 gene expression and uses thereof
WO2007137156A8 (en) Rnai modulation of aha and therapeutic uses thereof
WO2009029293A3 (en) Nucleic acid compounds for inhibiting myc gene expression and uses thereof
WO2010006973A3 (en) Compositions and methods for inhibiting expression of tgf-beta receptor genes
WO2010017311A3 (en) Nucleic acid compounds for inhibiting birc5 gene expression and uses thereof
WO2008109352A3 (en) Nucleic acid compounds for inhibiting akt gene expression and uses thereof
WO2007137220A3 (en) Compositions and methods for inhibiting expression of ikk-b gene
WO2008109558A3 (en) Nucleic acid compounds for inhibiting tlr gene expression and uses thereof
WO2008109469A3 (en) Nucleic acid compounds for inhibiting pcna gene expression and uses thereof
WO2008109375A3 (en) Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
WO2008109350A3 (en) Nucleic acid compounds for inhibiting il6 gene expression and uses thereof
WO2008109366A3 (en) Nucleic acid compounds for inhibiting ccnd1 gene expression and uses thereof
WO2008109546A3 (en) Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
WO2008109548A3 (en) Nucleic acid compounds for inhibiting tgfb gene expression and uses thereof
WO2008109443A3 (en) Nucleic acid compounds for inhibiting cdk2 gene expression and uses thereof
WO2008109495A3 (en) Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof
WO2008109506A8 (en) Nucleic acid compounds for inhibiting jun gene expression and uses thereof
WO2008109487A3 (en) Nucleic acid compounds for inhibiting mme gene expression and uses thereof
WO2008109364A3 (en) Nucleic acid compounds for inhibiting frap1 gene expression and uses thereof
WO2008109493A3 (en) Nucleic acid compounds for inhibiting cd19 gene expression and uses thereof
WO2008109547A3 (en) Nucleic acid compounds for inhibiting tymp gene expression and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731286

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08731286

Country of ref document: EP

Kind code of ref document: A2